Combined Total Sleep Deprivation and Light Therapy in the Treatment of Drug-Resistant Bipolar Depression: Acute Response and Long-Term Remission Rates.[CME]
J Clin Psychiatry 2005;66(12):1535-1540
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Drug resistance remains a
persistent source of morbidity and mortality for
patients with bipolar depression. A growing number of clinical studies support the usefulness
of chronotherapeutic interventions, such as total sleep deprivation (TSD) and light therapy (LT),
in the treatment of nonresistant bipolar depression.
Method: To investigate the clinical
usefulness of TSD plus LT in the treatment of
drug-resistant bipolar depression, we treated 60 inpatients for
1 week with repeated TSD and LT combined with ongoing antidepressants and lithium salts.
All patients had a DSM-IV diagnosis of bipolar I
disorder. Drug resistance was rated according to Thase and Rush criteria. The pattern of
relapses and recurrences was assessed during a
prospective 9-month follow-up. Data were gathered
from September 2002 to July 2004.
Results: A 2-way repeated-measures
analysis of variance with changes in self-rated
perceived mood scores as dependent variable and with
time and group (history of drug resistance) as
independent factors confirmed significant
time-by-group interaction (p = .0339). A logistic regression
on rates of achievement of response (50% reduction in Hamilton Rating Scale for Depression
ratings) confirmed the significance of observed
differences: overall, 70% (23/33) of nonresistant
versus 44% (12/27) of drug-resistant patients
achieved response (p = .045). A survival time analysis
(Cox proportional hazards model) showed that
history of drug resistance significantly influenced
the pattern of relapses and recurrences, with 57% (13/23) of nonresistant responders and 17%
(2/12) of drug-resistant responders being euthymic after 9 months (p = .0212).
Discussion: The combination of repeated
TSD and LT in drug-resistant patients was useful
in triggering an acute response. Further clinical
research is needed to optimize this treatment
option for drug-resistant patients in the long term.